[1]杨丽青,刘　威.乙醛脱氢酶1在乳腺癌转移淋巴结中的表达及其临床意义[J].新乡医学院学报,2019,36(10):945-948.[doi:10.7683/xxyxyxb.2019.10.010]
　YANG Li-qing,LIU Wei.Expression of aldehyde dehydrogenase 1 in metastatic lymph node of breast cancer and its clinical significance[J].Journal of Xinxiang Medical University,2019,36(10):945-948.[doi:10.7683/xxyxyxb.2019.10.010]
点击复制

乙醛脱氢酶1在乳腺癌转移淋巴结中的表达及其临床意义
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
36
期数:
2019年10
页码:
945-948
栏目:
临床研究
出版日期:
2019-10-05

文章信息/Info

Title:
Expression of aldehyde dehydrogenase 1 in metastatic lymph node of breast cancer and its clinical significance
作者:
杨丽青; 刘　威
（广州市红十字会医院，暨南大学医学院附属广州红十字会医院乳腺科，广东　广州　510220）
Author(s):
YANG Li-qing; LIU Wei
（Department of Breast,Guangzhou Red Cross Hospital,Medical College,Jinan University,Guangzhou 510220,Guangdong Province,China）
关键词:
乳腺癌; 淋巴结转移; 乙醛脱氢酶1
Keywords:
breast cancer; lymph node metastasis; aldehyde dehydrogenase 1
分类号:
R737.9
DOI:
10.7683/xxyxyxb.2019.10.010
文献标志码:
A
摘要:
目的　探讨乙醛脱氢酶1(ALDH1)在乳腺癌转移淋巴结中的表达及其临床意义。方法　收集2012年2月至2014年1月在广州市红十字会医院行乳腺癌手术患者的临床资料，采用免疫组织化学染色法检测乳腺癌转移淋巴结（n=47）和未转移淋巴结(n=15)中ALDH1的表达，分析转移淋巴结中ALDH1表达与乳腺癌患者临床病理特征及预后的关系。结果　乳腺癌转移淋巴结和未转移淋巴结中ALDH1阳性表达率分别为36.17%（17/47）、6.67%（1/15），转移淋巴结中ALDH1阳性表达率显著高于未转移淋巴结 (χ2=4.804,P<0.05)。乳腺癌转移淋巴结中ALDH1表达与患者肿瘤临床分期、肿瘤直径、雌激素受体、孕激素受体、人类表皮生长因子受体2、Ki-67表达及原发灶分子分型无关(P>0.05)，与肿瘤分级及淋巴结转移数有关(P<0.05)。乳腺癌转移淋巴结ALDH1表达阳性患者和ALDH1表达阴性患者5 a生存率分别为82.4%（14/17）、90.0%（27/30），乳腺癌转移淋巴结ALDH1表达阳性患者与ALDH1表达阴性患者5 a生存率比较差异无统计学意义(χ2=0.576，P>0.05)。结论　乳腺癌转移淋巴结中ALDH1表达与原发灶肿瘤分级、淋巴结转移数相关，但转移淋巴结中ALDH1表达与患者预后无关。
Abstract:
Objective　To study the expression of aldehyde dehydrogenase 1 (ALDH1) in metastatic lymph nodes of breast cancer and its clinical significance.Methods　The clinical data of breast cancer patients who underwent operation in Guangzhou Red Cross Hospital from February 2012 to January 2014 were collected.The expression of ALDH1 in 47 cases of metastatic lymph nodes and 15 cases of non-metastatic lymph nodes was detected by immunehistochemical staining method.The relationship between the expression of ALDH1 and clinic pathological parameters,prognosis of breast cancer patients was analyzed.Results　The positive expression rate of ALDH 1 in metastatic and non-metastatic lymph nodes of breast cancer was 36.17% (17/47) and 6.67% (1/15),respectively.The positive expression rate of ALDH1 in metastatic lymph nodes was significantly higher than that in the non-metastatic lymph nodes (χ2=4.804,P<0.05).The expression of ALDH1 in metastatic lymph nodes of breast cancer was not related to clinical stage,tumor diameter,expression of estrogen receptor,progesterone,Ki-67 and human epidermal growth factor receptor 2 and the molecular typing of primary lesions (P>0.05),but it was related to tumor grade and lymph node metastasis (P< 0.05).The 5-year survival rate of patients with positive expression of ALDH1 and negative expression of ALDH1 in metastatic lymph nodes of breast cancer was 82.4%（14/17），90.0%（27/30），respectively；there was no significant difference in 5-year survival rate between patients with positive expression of ALDH1 and negative expression of ALDH1 in metastatic lymph nodes of breast cancer (χ2= 0.576,P>0.05).Conclusion　The expression of ALDH1 in metastatic lymph nodes of breast cancer is correlated with the grade of primary tumor and the number of lymph node metastases,but the expression of ALDH1 in metastatic lymph node is not correlated with the prognosis of patient.

参考文献/References:

［1］　OMARINI C,GUAITOLI G,PIPITONE S,et al.Neoadjuvant treatments in triple-negative breast cancer patients:where we are now and where we are going ［J］.Cancer Manag Res,2018,15(10):91-103.
［2］　LIN C Y,BARRY-HOLSON K Q,ALLISON K H,et al.Breast cancer stem cells：are we ready to go from bench to beside ［J］.Histopathology,2016,68(1):119-137．
［3］　TOMITA H,TANAKA K,TANAKA T,et al.Aldehyde dehydro-genase 1A1 in stem cells and cancer［J］.Oncotarget,2016,7(10):11018-11032.
［4］　BALICKI D.Moving forward in human mammary stem cell biology and Breast cancer prognostication using ALDH1 ［J］.Cell Stem Cell,2007,1(5):485-487.
［5］　ZHOU L,JIANG Y,YAN T,et al.The prognostic role of cancer stem cells in breast cancer:a meta-analysis of published literatures ［J］.Breast Cancer Res Treat,2010,122(3):795-801.
［6］　FROMOEITZ F B,VIOLA M V,CHAO S,et al.Ras p21 expre-ssion in the progression of breast cancer［J］.Hum Pathol,1987,18(12):1268-1275．
［7］　TOBIN N P,HARRELL J C,LOVROT J,et al.Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival ［J］.Ann Oncol,2015,26(1):81-88.
［8］　BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global can-cer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2018,68(6):394-424.
［9］　BATLLE E,CLEVERS H.Cancer stem cells revisited［J］.Nat Med,2017,23(10):1124-1134.
［10］　ALHAJJ M,WICHA M S,MORRISON S J,et al.Prospective identification of tumorigenic breast cancer cells［J］.Proc Natl Acad Sci USA,2003,100(7):3983-3988.
［11］　钟瑾怡，成丛丛，徐金媛，等.多柔比星通过Stat3-Oct-4/CD44途径诱导三阴性乳腺癌4T1细胞干性的产生［J］.中国病理生理杂志，2019，35(2):360-364.
［12］　DACRUZ P A,LOPES C.Implications of different cancer stem cell phenotypes in breast cancer ［J］.Anticancer Res,2017,37（5）:2173-2183.
［13］　LEVIB P,YILMAZO H,DUESTER G,et al.Aldehyde dehydro-genase 1a1 is dispensable for stem cell function in the mouse hematopoietic and nervous systems ［J］.Blood,2009,113(8):1670-1680.
［14］　DEMIR H,DULGAR O,GULLE B T,et al.Prognostic value of al-dehyde dehydrogenase 1 (ALDH1) in invasive breast carcinomas ［J］.Bosn J Basic Med Sci,2018,18(4):313-319.
［15］　SAKAKIBARA M,FUJIMORI T,MIYOSHI T,et al.Aldehyde de-hydrogenase 1-positive cells in axillary lymph node metastases after chemotherapy as a prognostic factor in patients with lymph node-positive breast cancer ［J］.Cancer,2012,118（16）:3899-3910.
［16］　NOGAMI T,SHIEN T,TANAKA T,et al.Expression of ALDH1 in axillary lymph node metastases is a prognostic factor of poor clinical outcome in breast cancer patients with 1-3 lymph node metastases ［J］.Br Cancer,2014,21（1）:58-65.
［17］　申美莹.ALDH1在乳腺癌前哨淋巴结中表达的临床价值研究［D］.汕头：汕头大学，2015.

相似文献/References:

[1]李体平． 张建辰 李军.胸段食管癌222例淋巴结转移情况分析[J].新乡医学院学报,2000,17(04):296.
[2]杨忠,徐坚民,黄国鑫,等.从MRI的表现探讨鼻咽癌生长方式及淋巴结转移的规律[J].新乡医学院学报,2001,18(06):399.
[3]张光谋,吴俊琢,徐振平,等.抗细胞凋亡基因bcl一2在乳腺癌中的表达[J].新乡医学院学报,2001,18(03):160.
[4]刘玉生 ． 万里,李森恺.乳腺癌切除即期乳房再造[J].新乡医学院学报,2001,18(01):023.
[5]王承正,张锦瑜,邱树升,等.C—erbB一2与ER、PS一2在乳腺癌中的表达及其临床相关性[J].新乡医学院学报,2003,20(05):324.
[6]王承正,张锦瑜,邱树升,等.C2erbB22 与ER、PS22 在乳腺癌中的表达及其临床相关性[J].新乡医学院学报,2003,20(05):324.
[7]王志民,段西华,祁天义,等.多点皮瓣固定法预防乳腺癌术后皮下积液效果观察 [J].新乡医学院学报,2007,24(03):287.
[8]郭兰青.乳腺癌患者生活质量影响因素[J].新乡医学院学报,2008,25(06):637.
[9]曹兴玥,赵庆伟,靳艳,等.CD44和nm23在乳腺浸润性导管癌中的表达及其与淋巴结转移的关系[J].新乡医学院学报,2011,28(01):042.
[10]靳艳,曹兴玥,赵庆伟,等.CD62P在人乳腺癌组织中的表达及其与淋巴结转移的关系[J].新乡医学院学报,2011,28(01):045.

更新日期/Last Update: 2019-10-05